Skip to content Skip to footer
Boehringer Ingelheim

Boehringer Ingelheim and AimedBio Partner to Advance an ADC Therapeutic in Oncology

Shots:BI has entered into a global collaboration & licensing agreement with AimedBio to develop a novel ADC for a broad range of cancers, expanding NBE Therapeutics’ portfolio (BI subsidiary)As per the deal, AimedBio will receive ~$991M, incl. an upfront, development & regulatory milestones, plus commercial milestones, as well as net sales-based royaltiesAimedBio’s…

Read more

Enhancing R&D Prowess in Oncology: Denis R. Beckford-Vera from Champions Oncology in Conversation with PharmaShots 

Shots: The complexity of human physiology continues to challenge drug development, as conventional models often fail to provide critical insights, resulting in high attrition rates Champions Oncology bridges this gap through patient-derived xenograft and ex vivo platforms built from real tumors, integrated with radiolabeled compounds for deeper R&D insights Denis R. Beckford-Vera, Head of Radiopharmacology…

Read more

Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots 

Shots: RenovoRx, a clinical-stage life sciences company, is developing targeted oncology therapies and has created RenovoCath, an FDA-cleared novel drug delivery device. Its proprietary TAMP therapy platform enables precise delivery of therapeutics across the arterial wall near the tumor site, directly targeting the tumor while potentially reducing the toxicities linked to systemic IV chemotherapy. In…

Read more

Navigating Amorphous Calcium Carbonate Therapies: Eden Ben from Amorphical in Conversation with PharmaShots 

Shots: ACC therapies introduce a novel treatment approach by modulating local pH, promoting bone remodeling, and reducing inflammation, with potential applications in osteoarthritis, calcium deficiencies, late-stage cancers, and bone disorders. Amorphical’s AMOR-18 showed encouraging results in an interim Phase II clinical trial involving COVID-19 patients. PharmaShots speaks with Eden Ben, CEO of Amorphical, to discuss…

Read more

Avant Technologies and Austrianova Form Joint Venture Klothonova to Develop Klotho-Based Cell Therapies

Shots:Avant Technologies and Austrianova signed a joint venture and licensing agreement to form Klothonova, a 50/50 Nevada-based Joint Venture focused on developing cell-based therapies using encapsulated Klotho-producing cellsUnder the terms of the agreement, Klothonova will leverage Austrianova’s proprietary cell-encapsulation technology to develop and commercialize therapies for Alzheimer’s disease, heart disease, cancer, kidney disease,…

Read more

Top 20 Oncology Companies of 2025 

Shots: ADCs, cell therapies, and radioligand therapies are reshaping oncology, while biopharma companies focus on smarter trials, patient-first approaches, and faster access to bridge unmet needs in cancer care In 2024, the global oncology market was valued at $225.01B and is projected to reach $668.26B by 2034, reflecting a strong CAGR of 11.5% from 2025…

Read more

Novatim Immune Therapeutics (Keyi Pharmaceutical) Inks a ~$1.16B Licensing Deal with RADIANCE Biopharma for KY-0301 to Treat Cancer

Shots:Novatim has entered into an exclusive global licensing agreement (excl. China) with RADIANCE Biopharma for KY-0301 to treat cancer As per the deal, RADIANCE Biopharma will receive rights to develop, register, & commercialize KY-0301 globally (excl. China) in exchange for $15M upfront, ~$150M in R&D & registration milestones & ~$1B in commercial milestone, with progressive…

Read more

Bayer Enters a ~$1.3B Deal with Kumquat Biosciences to Develop and Commercialize a KRAS G12D Inhibitor

Shots:Bayer has entered into an exclusive global license agreement & collaboration with Kumquat Biosciences to develop and commercialize its KRAS G12D inhibitorKumquat will initiate & complete the P-Ia study following FDA’s IND clearance in Jul 2025, while Bayer handles further development & commercialization, with Kumquat holding an exclusive option to negotiate US profit-loss…

Read more